Home207940 • KRX
add
Samsung Biologics Co Ltd
Previous close
₩1,017,000.00
Day range
₩1,019,000.00 - ₩1,039,000.00
Year range
₩907,000.00 - ₩1,209,000.00
Market cap
73.31T KRW
Avg Volume
73.62K
P/E ratio
57.01
Dividend yield
-
Market news
Financials
Income Statement
Revenue
Net income
| (KRW) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | 1.29T | 11.50% |
Operating expense | 239.48B | 8.55% |
Net income | 324.39B | 2.01% |
Net profit margin | 25.15 | -8.51% |
Earnings per share | 4.56K | 2.01% |
EBITDA | 653.80B | 12.23% |
Effective tax rate | 20.67% | — |
Balance Sheet
Total assets
Total liabilities
| (KRW) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 1.64T | 4.85% |
Total assets | 17.77T | 8.75% |
Total liabilities | 6.17T | 2.60% |
Total equity | 11.60T | — |
Shares outstanding | 71.17M | — |
Price to book | 6.24 | — |
Return on assets | 6.75% | — |
Return on capital | 9.25% | — |
Cash Flow
Net change in cash
| (KRW) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | 324.39B | 2.01% |
Cash from operations | 523.38B | 118.57% |
Cash from investing | -540.29B | -70.43% |
Cash from financing | -2.62B | 91.92% |
Net change in cash | -42.58B | 50.81% |
Free cash flow | 251.99B | 144.79% |
About
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. Wikipedia
CEO
Founded
2011
Website
Employees
4,770
